Search
"Extravasation of intravenous iron at the site of infusion leads to the iron accumulation in the dermis, resulting in persistent hyperpigmentation that ranges from grayish to brown, known as cutaneous siderosis" Lee et al (2024).
Treatment of intravenous iron extravasation

Extract:

“Extravasation of intravenous iron at the site of infusion leads to the iron accumulation in the dermis, resulting in persistent hyperpigmentation that ranges from grayish to brown, known as cutaneous siderosis. Ferinject, containing ferric carboxymaltose, is a contemporary iron (III)-hydroxide carbohydrate complex intended for intravenous application. While rare, extravasation at the injection site has been reported, with the highest incidence observed at 2.2% in a study involving 139 patients with chronic kidney disease not requiring dialysis. Previous reports have described the treatment of cutaneous siderosis using various lasers, including the 755-nm Q-switched (QS) alexandrite laser, the 532-nm QS Nd:YAG laser, and the 964-nm QS ruby laser.”

Reference:

Lee W, Eun YS, Kim JY, Lee SH, Kim Y, Kim JE. Successful treatment of cutaneous siderosis using a 1064-nm Nd:YAG picosecond laser following intravenous iron extravasation: A case report. J Cosmet Dermatol. 2024 May 30. doi: 10.1111/jocd.16416. Epub ahead of print. PMID: 38813826.

Register for free citation alerts

Supporting your vascular access and infusion therapy learning journey